Financial Review: AlloVir (NASDAQ:ALVR) and LadRx (OTCMKTS:CYTR)

Risk & Volatility

LadRx has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Earnings & Valuation

This table compares LadRx and AlloVir”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A
AlloVir	N/A	N/A	-$190.42 million	($20.23)	-0.27

AlloVir is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.1% of LadRx shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares LadRx and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LadRx	N/A	-67.61%	-45.39%
AlloVir	N/A	-71.03%	-61.27%

Summary

LadRx beats AlloVir on 5 of the 8 factors compared between the two stocks.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

About AlloVir

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.